Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 11/20 | 0.73 |
| ▸ | APP | P05067 | 2/20 | 0.67 |
| ▸ | MAOA | P21397 | 3/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | DHFR | P00374 | 1/20 | 0.61 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.59 |
| ▸ | TEC | P42680 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11664961 | 1.00 | MAOB (0.73) | MAOBAPPMAOAGAAMAPT | |
| SCHEMBL5121663 | 0.89 | MAOB (0.80) | MAOBAPPMAOAGAAMAPT | |
| SCHEMBL10991891 | 0.89 | MAOB (0.80) | MAOBAPPMAOARAB9ADHFR | |
| SCHEMBL31542030 | 0.89 | MAOB (0.80) | MAOBAPPMAOAGAAMAPT | |
| SCHEMBL4023130 | 0.84 | MAOB (1.00) | MAOBAPPMAOADHFRNR4A2 | |
| SCHEMBL18983634 | 0.82 | MAOB (0.58) | MAOBAPPMAOAGAAMAPT | |
| SCHEMBL11600066 | 0.82 | MAOB (0.69) | MAOBAPPMAOARAB9ADHFR | |
| SCHEMBL5511971 | 0.82 | MAOB (0.69) | MAOBAPPMAOAMAPTRAB9A | |
| SCHEMBL29590693 | 0.82 | MAOB (0.69) | MAOBAPPMAOAGAAMAPT | |
| SCHEMBL3624903 | 0.82 | MAOB (0.69) | MAOBAPPMAOARAB9ADHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3976027-B1 | QUINOLINE DERIVATIVES AS FACTOR XI ACTIVATION INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-11-05 | — | — | EP | disclosed |
| US-12304899-B2 | Factor XI activation inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-05-20 | — | — | US | disclosed |
| US-20220235033-A1 | FACTOR XI ACTIVATION INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-07-28 | — | — | US | disclosed |
| EP-3976027-A1 | FACTOR XI ACTIVATION INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2022-04-06 | — | — | EP | disclosed |
| EP-3760633-B1 | OXAZINO-QUINAZOLINE AND OXAZINO-QUINAZOLINE TYPE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2021-12-15 | — | — | EP | disclosed |
| EP-3760633-A1 | OXAZINO-QUINAZOLINE AND OXAZINO-QUINAZOLINE TYPE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF | Beijing Scitech-MQ Pharmaceuticals Limited (CN) | 2021-01-06 | — | — | EP | disclosed |
| WO-2020243049-A1 | FACTOR XI ACTIVATION INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-12-03 | — | — | WO | disclosed |
| US-10617706-B2 | Compounds for cancer chemotherapeutic sensitization | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2020-04-14 | — | — | US | disclosed |
| US-20190240244-A1 | COMPOUNDS FOR CANCER CHEMOTHERAPEUTIC SENSITIZATION | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2019-08-08 | — | — | US | disclosed |
| WO-2013014445-A1 | DERIVATIVES OF PHENYL (THIO) UREA DEOXYTHYMIDINE AND USE THEREOF AS ANTIMALARIALS | UNIVERSITY OF DUNDEE (GB) | 2013-01-31 | — | — | WO | disclosed |
| EP-0446731-A2 | Process for the manufacture of azo dyes | BAYER AG (DE) | 1991-09-18 | — | — | EP | disclosed |
| EP-0113922-A2 | Process for the manufacture of cationic methine dyes | BAYER AG (DE) | 1984-07-25 | — | — | EP | disclosed |
| EP-0113920-A2 | Process for the manufacture of stable solutions of cationic methine dyes, and their use in spin dyeing | BAYER AG (DE) | 1984-07-25 | — | — | EP | disclosed |
| EP-0113921-A2 | Process for the manufacture of stable solutions of cationic methine dyes | BAYER AG (DE) | 1984-07-25 | — | — | EP | disclosed |
| EP-0042556-B1 | PROCESS FOR THE MANUFACTURE OF ALKYLHYDRAZONE CATIONIC DYES AND THEIR DYESTUFF BASES | BAYER AG (DE) | 1984-02-08 | — | — | EP | disclosed |
| US-4376728-A | Process for the preparation of cationic alkylarylhydrazone dyestuffs and color bases thereof | BAYER AKTIENGESELLSCHAFT (DE) | 1983-03-15 | — | — | US | disclosed |
| EP-0042556-A2 | Process for the manufacture of alkylhydrazone cationic dyes and their dyestuff bases | BAYER AG (DE) | 1981-12-30 | — | — | EP | disclosed |
| US-4074057-A | HYPERLIPEMIA, DIABETES | TAKEDA CHEMICAL CO., LTD. (JA) | 1978-02-14 | — | — | US | disclosed |
| US-3975379-A | METHINE | BAYER AKTIENGESELLSCHAFT (DT) | 1976-08-17 | — | — | US | disclosed |
| US-3956264-A | Basic azo dyestuffs having indolyl-methyleneamino substituent in the diazo component | BAYER AKTIENGESELLSCHAFT (DT) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12304899-B2 | Factor XI activation inhibitors | F11, TFPI, F13B | MAOB 312/4885APP 2437/4885MAOA 410/4885 |
| US-10617706-B2 | Compounds for cancer chemotherapeutic sensitization | ABCC1, MCL1, ABCC3 | MAOB 4336/4885APP 4810/4885MAOA 4652/4885 |
| US-20220235033-A1 | FACTOR XI ACTIVATION INHIBITORS | F11, TFPI, F13B | MAOB 312/4885APP 2437/4885MAOA 410/4885 |
| US-20190240244-A1 | COMPOUNDS FOR CANCER CHEMOTHERAPEUTIC SENSITIZATION | ABCC1, MCL1, ABCC3 | MAOB 4336/4885APP 4810/4885MAOA 4652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.